Age dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction - a multicenter retrospective observational study of young versus old patients

CONCLUSION: Old patients benefit less from neoadjuvant treatment compared to younger patients in terms of gain in overall survival. Since they also experience more side effects requiring dose reduction, upfront surgery should be considered as the primary treatment option in elderly …